Navigation Links
ENDECE Neural to Present Findings for Remyelination at 2013 Keystone Symposia on Multiple Sclerosis
Date:11/28/2012

MEQUON, Wis., Nov. 28, 2012 /PRNewswire/ -- ENDECE Neural, LLC (www.EndeceNeural.com) announced today that Dr. Steven Nye, Vice President of Discovery, will be presenting at the 2013 Keystone Symposia on Multiple Sclerosis to be held in January, in Big Sky, Montana, USA. 

Dr. Nye's presentation, "Estrogen analogs dramatically up-regulate intracellular signaling pathways for remyelination (1)," will review the mechanism behind the novel ENDECE Neural compounds that induce remyelination in rodent animal models of Multiple Sclerosis (MS). 

"Unlike current MS therapeutics, which target immune response and inflammation to slow relapses, ENDECE Neural is developing the first drug compounds to induce remyelination of demyelinated axons, and potentially reverse disease progression," states Dr. Nye.

Abstract below:
Estrogen analogs dramatically up-regulate intracellular signaling pathways for remyelination.

A new series of nuclear receptor ligands was synthesized for treating multiple sclerosis and other neurodegenerative disorders. The ligands are analogs of 17beta-estradiol (E2) that bind to the estrogen receptors (ERs) and induce distinct intracellular responses which can determine cell fate. Based on molecular modeling studies, modifications to the core structure of E2 were made with different C-6 alkoxyalkyl moieties and/or substitution of the C-18 methyl group. The E2 alterations caused pronounced changes in subtype selectivity for ER-alpha or ER-beta, along with varying degrees of ER dimerization and ER activation. Microarray studies revealed that several of the E2 analogs cause a dramatic up-regulation of genes in signaling pathways related to OPC differentiation and myelin sheath production. While all three E2 analogs are ER agonists, NDC-1308 was the most potent at causing mouse OPC differentiation concomitant with myelin basic protein expression in vitro. The findings presented here relate the structure of the E2 analogs to biological function. We conclude that cellular responses for neuronal repair/remyelination may be controlled to some extent by making key alterations to the core structure of endogenous ER ligands. 

(1) Steven H. Nye, ENDECE, LLC, Mequon, WI, USA 53092; Wei Xu, University of Wisconsin, McArdle Laboratory for Cancer Research, Madison, WI, USA 53706; Michael Bittner, Translational Genomics Research Institute, Scottsdale, AZ, USA 85004; Robert E. Babine, Rebexsess Discovery Chemistry, Encinitas, CA, USA 92024;  James G. Yarger, ENDECE, LLC, Mequon, WI, USA 53092.

About ENDECE Neural, LLC (an ENDECE Company)
ENDECE Neural is the wholly owned subsidiary of ENDECE, LLC. ENDECE Neural was founded in 2011 to focus on the development of what could be the first drug capable of inducing remyelination of damaged nerve axons, and potentially restoring muscle control, mobility and independence to the lives of Multiple Sclerosis patients. ENDECE Neural maintains an exclusive license for the IP from its parent company.


'/>"/>
SOURCE ENDECE Neural, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuralstem Updates ALS Stem Cell Trial Progress
2. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
3. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
6. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
7. Neuralstem Announces Proposed Public Offering
8. Neuralstem to Raise $7.0 Million in Registered Direct Offering
9. Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
10. MRI Interventions Named 2012 Global Company of the Year in Image-Guided Neural Interventions
11. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Sun Chlorella Corp ., the California -based ... Non-GMO Project Verification and the launch of individual serving packets ... for the Natural Products Expo West trade show, March 10-12 ... Chlorella Corp. has announced the Non-GMO Project Verification logo is ... Sun Chlorella tablets, 250mg and 500mg (20/100-day supplies) ...
(Date:3/1/2017)... March 1, 2017  Integrated Modular Design ... design and implementation of pre-fabricated healthcare products ... room headwalls, seeks to lead the construction ... solutions. Fueled by their leading-edge ... of reducing construction timelines and project risk, ...
(Date:3/1/2017)... , March 1, 2017  Global biotherapeutics leader ... the largest ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, ... T reatment with H izentra ® ).  ... the efficacy, safety and tolerability of two different doses ... (Immune Globulin Subcutaneous [Human]), compared with placebo, in the ...
Breaking Medicine Technology:
(Date:3/1/2017)... Calif. (PRWEB) , ... March 01, 2017 , ... Award-winning ... has completed 25 medical mission trips in underdeveloped nations, averaging more than one trip ... 2016. An article on the website features the details of his charitable ...
(Date:3/1/2017)... ... March 01, 2017 , ... NYC based Integrated practice Living Well ... to announce the addition of Orthopaedic Surgeon Dr. Donald E. Heitman. Dr. ... Cornell University with a Bachelor of Science degree in biology. He then obtained his ...
(Date:3/1/2017)... ... 01, 2017 , ... “There is Comfort for the Soul”: a loving account ... their all-too-brief time together, and the soul-healing comfort provided by God’s presence in the ... published author, Jerie A. Tau, a dog-loving medical professional whose work takes her to ...
(Date:3/1/2017)... ... ... Way: Key To One Flesh”: a collection of real marital scenarios and solutions for ... Cecilia Chiam, a writer who emigrated to the United States in 1978. , ... problems with the guidance and support of Holy Scripture. , “This is a ...
(Date:3/1/2017)... ... March 01, 2017 , ... Adherence Compliance, the ... Cannabis Compliance Program for Regulatory Agencies. The regulatory agency program is the first ... internal or outsourced compliance program options, as well as an app for inspections ...
Breaking Medicine News(10 mins):